Roche has announced a new collaboration with Macrocyclics, a member of the Areva group, to continue development of a novel chelating agent for use in radioimmunotherapy. This is the second collaboration between the two companies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
